Home > Healthcare > Medical Devices > Therapeutic Devices > Photopheresis Products Market

Photopheresis Products Market Trends

Report ID: GMI5958
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Photopheresis Products Market Trends

Increased government reimbursement policies and growing private healthcare insurance regarding photopheresis products are anticipated to stimulate market gains. Government reimbursement policies and expanded private healthcare insurance coverage can increase patient access to photopheresis treatment. By providing financial support, these policies make the treatment more affordable for patients, thereby increasing the demand for photopheresis products. This can lead to increased competition, innovation, and product development, benefiting healthcare providers and patients by providing a wider range of options and advancements in photopheresis technology.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The global market for photopheresis products was valued at over USD 270 million in 2022 and is projected to reach more than USD 440 million by 2032. The growing prevalence of autoimmune diseases is accelerating market growth as these products are primarily used for the treatment of certain blood disorders and immune-mediated conditions.

The closed system segment held a notable revenue share of over USD 150 million in 2022 and will reach more than USD 240 million by 2032, as these closed systems are designed to minimize the risk of contamination during the photopheresis procedure.

The U.S. region accounted for more than USD 95 million in 2022 and will be worth over USD 150 million by 2032, backed by the affordability of photopheresis products among the target population base and ongoing technological developments.

Haemonetics Corporation, Fresenius Kabi, Terumo Corporation, Macopharma, Mallinckrodt Pharmaceuticals, Med Tech Solutions GmbH, Thermo Fisher Scientific, Spectranetics, Therakos, among others.